再遭艾伯维诉讼？百济神州AH股双双大跌

读创客户端09-12

深圳商报·读创客户端记者陈燕青在连续上涨后，百济神州AH股12日大跌。截至记者发稿时，百济神州A股大跌10%，H股下跌6%。尽管大跌，但百济神州三季度表现依然抢眼，H股三季度至今大涨36%，A股大涨25%。有外媒称，上周五艾伯维诉讼百济神州，指控其窃取商业机密，涉及的项目是BTK CDAC。艾伯维提到其前雇员涉嫌窃取艾伯维 BTK降解剂的商业机密和机密信息，将这些信息披露给百济神州，并最终使用...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2466472246?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-12 14:49","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2466472246","market":"us","top_or_hot":-1,"title":"再遭艾伯维诉讼？百济神州AH股双双大跌","media":"读创客户端","content":"<div>\n<p>深圳商报·读创客户端记者 陈燕青在连续上涨后，百济神州AH股12日大跌。截至记者发稿时，百济神州A股大跌10%，H股下跌6%。尽管大跌，但百济神州三季度表现依然抢眼，H股三季度至今大涨36%，A股大涨25%。有外媒称，上周五艾伯维诉讼百济神州，指控其窃取商业机密，涉及的项目是BTK CDAC。艾伯维提到其前雇员涉嫌窃取艾伯维 BTK降解剂的商业机密和机密信息，将这些信息披露给百济神州，并最终使用...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912145427955f5556&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再遭艾伯维诉讼？百济神州AH股双双大跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再遭艾伯维诉讼？百济神州AH股双双大跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-12 14:49 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912145427955f5556&s=b><strong>读创客户端</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>深圳商报·读创客户端记者 陈燕青在连续上涨后，百济神州AH股12日大跌。截至记者发稿时，百济神州A股大跌10%，H股下跌6%。尽管大跌，但百济神州三季度表现依然抢眼，H股三季度至今大涨36%，A股大涨25%。有外媒称，上周五艾伯维诉讼百济神州，指控其窃取商业机密，涉及的项目是BTK CDAC。艾伯维提到其前雇员涉嫌窃取艾伯维 BTK降解剂的商业机密和机密信息，将这些信息披露给百济神州，并最终使用...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912145427955f5556&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0795875169.SGD","symbol_name":"JPMorgan Investment Funds - Global Income A (div) SGD-H","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912145427955f5556&s=b","article_id":"2466472246","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912145427955f5556&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2466472246","pubTimestamp":1726123747,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"截至记者发稿时，百济神州A股大跌10%，H股下跌6%。尽管大跌，但百济神州三季度表现依然抢眼，H股三季度至今大涨36%，A股大涨25%。有外媒称，上周五艾伯维诉讼百济神州，指控其窃取商业机密，涉及的项目是BTK CDAC。艾伯维提到其前雇员涉嫌窃取艾伯维 BTK降解剂的商业机密和机密信息，将这些信息披露给百济神州，并最终使用这些信息。百济神州的声明称艾伯维的诉讼是“为了阻碍”百济神州竞争性BTK降解剂BGB-16673的开发。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","06160":"百济神州","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4548":"巴美列捷福持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BGNE":"百济神州","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4534":"瑞士信贷持仓","ABBV":"艾伯维公司","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4566":"资本集团","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4535":"淡马锡持仓","LU0882574055.USD":"富达全球健康医疗A ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4559":"巴菲特持仓","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4550":"红杉资本持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD"},"translate_title":"Another AbbVie lawsuit? BeiGene AH shares both plummeted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":0.9,"BGNE":1,"ABBV":0.9,"06160":0.9},"content_text":"深圳商报·读创客户端记者 陈燕青在连续上涨后，百济神州AH股12日大跌。截至记者发稿时，百济神州A股大跌10%，H股下跌6%。尽管大跌，但百济神州三季度表现依然抢眼，H股三季度至今大涨36%，A股大涨25%。有外媒称，上周五艾伯维诉讼百济神州，指控其窃取商业机密，涉及的项目是BTK CDAC。艾伯维提到其前雇员涉嫌窃取艾伯维 BTK降解剂的商业机密和机密信息，将这些信息披露给百济神州，并最终使用这些信息。百济神州在周一的声明中否认了艾伯维的指控，并表示“公司将在这起诉讼中坚决捍卫我们的知识产权”。百济神州的声明称艾伯维的诉讼是“为了阻碍”百济神州竞争性BTK降解剂BGB-16673的开发。公司在艾伯维为其BTK降解剂提交专利申请之前，就已经提交了BGB-16673的专利申请。记者注意到，此次诉讼的焦点是两家公司研发的癌症治疗药物——“BTK降解剂”。百济神州的主要收入源于3款药，包括BTK降解剂百悦泽（泽布替尼胶囊）、PD-1抑制剂百泽安（替雷利珠单抗注射液）、PARP1和PARP2抑制剂百汇泽（帕米帕利）。今年上半年，百济神州营业收入首次突破100亿元，其中百悦泽创造的收入超过80亿元，同比增长122%。上半年，百悦泽来自美国的收入接近60亿元，来自欧洲的销售额超过10亿元，同比增长分别超过130%和230%。或许是在海外市场锋芒太盛让百悦泽惹上了官司。去年6月，跨国药企艾伯维指控百悦泽侵犯了伊布替尼（全球首款同类抗癌药）的专利，目前该专利的有效性仍悬而未决。对此，天风证券医药分析师杨松认为，公司作为全球创新药龙头企业，具备较为完善的知识产权管理体系，且结合现有信息分析，我们认为公司处于有利的一方。此外，相关诉讼行为并不影响公司产品临床推进，继续强烈看好公司，当前时点重点推荐。百济神州此前发布的中报显示，上半年公司实现营业收入119.96亿元，同比增长65.44%；实现归母净利润-28.77亿元，亏损同比减少44.87%，上年同期亏损52.19亿元。资料显示，百济神州是全球首家实现在上交所、纳斯达克、港交所上市的生物科技企业，拥有国内首个“十亿美元分子”，但也是最“亏本”的中国创新药企业之一。截至上半年末，公司累计未弥补亏损为605.66亿元。百济神州在研发方面投入巨大或许是其亏损较大的主要原因。过去近五年半，百济神州的研发费用支出超过500亿元，今年上半年，公司研发费用为66.28亿元。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466472246"}